Curis is a biotechnology company dedicated to pioneering first-in-class, innovative cancer therapies. With a robust pipeline of differentiated small-molecule drug candidates, Curis is currently focused on advancing emavusertib (CA-4948), an oral IRAK4 kinase inhibitor, for the treatment of non-Hodgkin’s lymphoma and leukemia (AML/MDS).